Drug Database
Back to search

Norway· NO-ID_9162A8C5-C5C7-4F7A-B5ED-A474884336C5

Depo-Provera

A medroxyprogesterone product containing medroxyprogesterone acetate, registered in Norway by Pfizer AS. The same ATC class is registered in 11 of our 19 countries.

ATC G03AC06

Checked against FEST (Norway) on

Informational only — not a medical device.

SOURCE REGISTER · NOFEST (Norway)normalisedDepo-ProveraATCG03AC06REGISTER NO.NO-ID_9162A8C5-C5C7-4…PACKS LISTED3CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about medroxyprogesterone acetateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Medroxyprogesterone is registered in 11 of 19 countries.

Countries holding a registration under ATC G03AC06 (medroxyprogesterone), each read from that country’s own register.

  • This record: Norway, from FEST (Norway)
  • 7 of them publish a price we can compare per daily dose
Search medroxyprogesterone products by name

Medroxyprogesterone · ATC G03AC06

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FEST (Norway)
Active substance
Medroxyprogesterone Acetate
Manufacturer
Pfizer AS
Country
Norway (NO)
ATC code
G03AC06
ATC class
Medroxyprogesterone
Defined daily dose
1.67 mg, P
Reimbursed
Not published by this register
Source register
FEST (Norway)
Last checked
September 25, 2026

Packs & prices · 3

1 priced
  • no_merkevare_id
    ID_9162A8C5-C5C7-4F7A-B5ED-A474884336C5
  • no_varenummer
    537209
    1
    NOK 105.8
  • gtin
    5415062314319

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

245 interactions on record for medroxyprogesterone.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check medroxyprogesterone against other medicinesHow interaction checks work

Medroxyprogesterone · interactions on record

245 records

  • 21 severe
  • 213 moderate
  • 7 minor

Most severe, free to view

  • Tranexamic acidB02AA02severe
  • BosentanC02KX01severe
  • GriseofulvinD01AA08severe
  • GriseofulvinD01BA01severe

4 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Medroxyprogesterone in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All medroxyprogesterone products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Depocon, Farlutal
  • Belgium · Depo-Provera, Provera
  • Bulgaria · Фарлутал
  • Czechia · Depo-Provera, Provera
  • Germany · Depo-Clinovir, Mpa
  • Denmark · Depo-Provera, Provera
  • Estonia · Farlutal
  • Spain · Depo-Progevera, Progevera
  • Finland · Farlutal, Provera
  • France · Depo Prodasone, Depo Provera
  • United Kingdom (Northern Ireland) · Depo-Provera, Medroxyprogesterone Acetate Pfizer
  • Croatia · Provera
  • Hungary · Depo-Provera, Provera
  • Ireland · Depo-Provera, Provera
  • Iceland · Depo-Provera
  • Italy · Depo-Provera, Farlutal
  • Luxembourg · Depo-Provera, Provera
  • Latvia · Depo-Provera
  • Netherlands · Depo-Provera, Provera
  • Poland · Depo-Provera, Provera
  • Portugal · Depo-Provera 150
  • Sweden · Depo-Provera, Provera

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/7b10ddb0-abe0-4908-a15a-78d29f8cd9c7
GET /v1/drugs/7b10ddb0-abe0-4908-a15a-78d29f8cd9c7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Injeksjonsvæske, suspensjon",
  "source": "fest",
  "status": "A",
  "atc_name": "Medroksyprogesteron",
  "merkevare_id": "ID_9162A8C5-C5C7-4F7A-B5ED-A474884336C5",
  "name_form_strength": "Depo-Provera inj væske, susp 150 mg/sprøyte",
  "prescription_group": "C"
}
API referenceMCP serverPlans

See everything about medroxyprogesterone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console